



Biosion next generation ADC platform will be presented at World ADC San Diego 2022

The 13th World ADC San Diego 2022 will be held from September 6 to 9. More than 600 ADC experts from around the world will attend the conference. Biosion will present the next-generation ADC development platform designed to identify the optimized antibodies with superior properties for ADCs.

In recent years, ADCs have become the focal point in the oncology space. In order to address the challenges of “differentiation,” Biosion has developed a next generation ADC platform: SynTracer™ HT-endocytosis platform.

Based on this platform, Biosion has solved the key challenge of antibody endocytosis in ADC development. The platform can efficiently screen for antibody candidates with high endocytosis activity. As a result, Biosion has developed a rich pipeline of next generation antibodies for ADCs. In December 2021, Biosion out-licensed BSI-04702, an anti-TROP2 antibody, to OBI Pharma, Inc. for worldwide (excluding the Chinese Mainland, Hong Kong, China, Macao, China) development and commercialization rights.

About SynTracer™ HT-endocytosis platform

The SynTracer™ HT-endocytosis platform enables identification of antibodies with efficient internalization rates, providing promising candidates for Antibody Drug Conjugates (ADCs).

The SynTracer™ platform allows for:

High-throughput endocytosis screening to identify the best internalizing antibodies.

Plug & play conjugation with a fixed DAR=2 to facilitate robust and efficient screening.

Simulation of ADC processes & MOA with high sensitivity, efficiency, and productivity.



About Biosion

Biosion is a global R&D biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived technologies including the H³ antibody discovery, SynTracer™ HT-endocytosis and Flexibody™ bispecific platforms. Biosion's lead asset, BSI-045B (anti-TSLP mAb), is currently in phase II for severe asthma in China and phase 1 for atopic dermatitis ex-China. Biosion and partners have plans to progress additional assets into the clinic for oncology indications over the next year. Biosion has operations in the US, Australia, and China. To learn more about Biosion visit www.biosion.com.